Home / Guides / Generic semaglutide
Status check · October 2026
Is there a generic semaglutide in the U.S.? Not yet. Here’s where things stand
Medically reviewed by the NexLife clinical team, led by Adam Kennah, MD (NPI 1144260043) · Updated
NexLife wrote this guide and offers compounded semaglutide, which isn’t a generic. No company named here reviewed or endorsed this guide.
No: as of October 27, 2026, no generic semaglutide has final FDA approval, and none is sold in the U.S. Apotex says it received the first tentative approval, for a generic Ozempic, in April 2026; that doesn’t allow sales. Novo Nordisk puts the U.S. expiry of its compound patent in 2032. Canada’s first generics launched in May 2026.
- U.S.: no generic on sale, and none with final FDA approval
- Canada: generic Ozempic launched in May 2026
- Compounded semaglutide: not a generic, and not FDA-approved
Where generic semaglutide stands
- United States
- No generic on sale, and none with final FDA approval. Apotex announced a tentative approval for its generic Ozempic (April 10, 2026), which doesn’t allow sales
- Canada
- Launched in May 2026: generic Ozempic from Apotex and Dr. Reddy’s, for type 2 diabetes
- Canada, for weight
- Approved: Apotex’s SEVMIA, a generic of Wegovy (announced June 30, 2026). We found no launch announcement yet
- India
- On the market: Dr. Reddy’s says it launched one there, Obeda, by May 2026
- Compounded semaglutide
- Not a generic, and not FDA-approved
- NexLife (compounded, not a generic)
- $119 a month on the 12-month plan ($139 month to month), at every dose
From each regulator’s or company’s own announcement, checked October 27, 2026. NexLife’s price from its pricing page.
Compounded semaglutide isn’t FDA-approved and isn’t a generic of Ozempic or Wegovy. A licensed provider prescribes it only when it offers a significant difference for you.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- No generic semaglutide is sold in the U.S. yet. As of October 27, 2026, none has final FDA approval: none is on the FDA’s 2026 list of first generics (through August 31, 2026) or in its monthly generic approvals for September and October (through October 26).
- A tentative approval isn’t an approval to sell. Apotex says it received the first, for a generic Ozempic, on April 10, 2026. The FDA says a tentative approval doesn’t let a company market the drug.
- Patents set the pace. Novo Nordisk puts the U.S. expiry of its semaglutide compound patent in 2032, and says the terms of its Ozempic patent settlements with seven generic makers, Apotex among them, are confidential.
- Canada is ahead. Generic Ozempic from Apotex and Dr. Reddy’s launched there in May 2026. But bringing drugs that aren’t FDA-approved into the U.S. for personal use is illegal in most cases, the FDA says.
- Compounded semaglutide isn’t a generic, and it isn’t FDA-approved either. At NexLife, it’s $119 a month on the 12-month plan, or $139 month to month, at every dose.
The status
Where is generic semaglutide sold, and why not in the U.S.?
Generics have launched in Canada and India. In the U.S., none has final FDA approval or is on sale. Each step, dated, as of October 27, 2026:
| Where | Status | Date | Source |
|---|---|---|---|
| United States | No generic semaglutide has final FDA approval or is on sale. Apotex says it received the first tentative approval, for its generic of Ozempic | April 10, 2026 (tentative) | Apotex; the FDA’s approval lists |
| Canadaapproval | Health Canada approved generic Ozempic from Dr. Reddy’s, the first in the G7, then from Apotex; both for type 2 diabetes | April 28, 2026 and May 1, 2026 | Health Canada, twice |
| Canadalaunch | Apotex and Dr. Reddy’s launched their generic Ozempic | May 2026 (Apotex: May 14, 2026) | Apotex; Dr. Reddy’s |
| Canadaweight management | Health Canada approved Apotex’s SEVMIA, a generic of Wegovy for chronic weight management in adults | Announced June 30, 2026 | Apotex |
| India | Dr. Reddy’s says it launched its generic semaglutide there, under the brand name Obeda | By May 2026 | Dr. Reddy’s |
Swipe the table sideways to see every column.
From each regulator’s or company’s own announcement, the FDA’s list of first generic approvals for 2026 (through August 31, 2026) and Drugs@FDA’s monthly generic approvals for September and October 2026 (through October 26), all checked October 27, 2026.
Others may be approved there. On May 1, 2026, Health Canada said it was reviewing seven more generic semaglutide submissions from other companies. This table lists only the approvals announced in the releases we cite.
Canada’s generic Wegovy, as Apotex describes it, comes in a pen that delivers 1 mg doses. We found no launch announcement for it on Apotex’s news page as of October 27, 2026.
None of these generics is FDA-approved. Below: what that means if you’re thinking of buying one abroad.
Tentative approval
What does a tentative approval mean?
It means the FDA found the generic ready for approval, but it can’t be sold yet. In the FDA’s words:
“A tentative approval does not allow the applicant to market the generic drug product.”
Why it waits: patents or exclusivity protecting the brand haven’t run out. The FDA delays final approval until those issues are resolved, its glossary says.
Apotex’s case. Apotex says its semaglutide injection, a generic version of Ozempic developed with Orbicular, received the FDA’s first tentative approval, and that it’s expected to help broaden access once it becomes eligible for final approval. We found no U.S. launch date in Apotex’s releases.
Ozempic, not Wegovy. Both are Novo Nordisk’s semaglutide: Ozempic for type 2 diabetes, Wegovy for weight management. Apotex’s U.S. tentative approval is for a generic of Ozempic. More: how semaglutide, Ozempic, Wegovy and Rybelsus differ.
Timing
When could generic Ozempic or Wegovy reach the U.S.?
No launch date is public. Patents, court cases and confidential settlements shape the timing; these are the dates that are public.
| Novo Nordisk’s compound patent | Its U.S. expiry is 2032, according to Novo Nordisk’s annual report for 2025 (Form 20-F). |
|---|---|
| The FDA’s Orange Book | Lists U.S. patent 8,129,343, marked as covering the drug substance, for both Ozempic and Wegovy, expiring December 5, 2031. It lists other patents too, some running later: to 2041 in the Wegovy pen listing we checked. |
| Generic applications | Several makers have applied to sell generic Ozempic, Wegovy and Rybelsus before some or all of Novo’s listed patents expire, and Novo has sued them for patent infringement, its report says. |
| Settlements | Novo has settled its U.S. patent cases over Ozempic with seven makers: Alvogen, Rio Biopharmaceuticals, Sun Pharmaceutical, Dr. Reddy’s, Mylan, Zydus and Apotex. Novo says all terms are confidential and subject to review by the FTC and the Justice Department. |
| A U.S. launch | None yet: no generic semaglutide has final FDA approval, as of October 27, 2026. |
What it means for you: there’s no public launch date. Generic makers can challenge listed patents, as several have, or settle, as seven have, and the settlement terms aren’t public. Novo’s report gives 2032 for its compound patent, while the Orange Book lists the drug-substance patent to 2031; we show both as published. So we don’t predict when a generic will launch.
For Zepbound and Mounjaro, see where generic tirzepatide stands.
Canada
Can you buy generic semaglutide from Canada?
Generics are sold there, but they aren’t FDA-approved, and bringing them home for personal use is illegal in most cases. The FDA’s words:
“In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S.”
Approved there isn’t approved here. The FDA adds that a drug approved in another country but not in the U.S. is illegal to import, and it recommends getting medicines only from legal sources in the U.S.
Canada’s generic Ozempic is for type 2 diabetes, like Ozempic here. Apotex’s generic Wegovy, SEVMIA, is for chronic weight management in adults; Apotex announced its approval on June 30, 2026.
A website selling “generic semaglutide” to Americans is a red flag. No generic is FDA-approved, so it’s selling a drug that isn’t approved here, or something that isn’t a generic at all. The FDA’s telehealth red flags include not requiring a screening and prescription by a licensed doctor, and claiming a compounded drug is the same as an FDA-approved one.
Legal ways to buy semaglutide online: where to buy semaglutide online, safely.
Compounded
Is compounded semaglutide a generic?
No. Compounded semaglutide isn’t a generic, and it isn’t FDA-approved. The FDA answers the question directly.
“No. A generic drug is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section (including establishing therapeutic equivalence to a brand name drug, among others), while a compounded drug is not approved by FDA.”
| A generic drug | Compounded semaglutide | |
|---|---|---|
| FDA approval | Approved by the FDA before it’s sold | Not FDA-approved: the FDA doesn’t verify its safety, effectiveness or quality before it’s sold |
| Compared with the brand | Must establish therapeutic equivalence to the brand-name drug | No equivalence review: the FDA doesn’t approve compounded drugs |
| Who makes it | A drug company, under its FDA approval | A state-licensed pharmacy, for one patient’s prescription |
| For semaglutide in the U.S. today | None with final approval; Apotex says it has a tentative one | Prescribed by a licensed provider only when it offers a significant difference for you |
Swipe the table sideways to see every column.
From the FDA’s compounding questions and answers and its page on unapproved
“Research use only” semaglutide isn’t a generic either. The FDA says products falsely labeled “for research purposes” or “not for human consumption” have been sold to people with dosing instructions, and it urges consumers not to buy them. What “research use only” really means.
More: compounded semaglutide vs. Ozempic and Wegovy and what compounded semaglutide is.
Prices now
What does semaglutide cost in the U.S. now?
Without a generic, these are the legal ways to pay. Each price comes from its seller’s own pages, with the date we checked it below.
| Option | A month | FDA-approved? | Good to know |
|---|---|---|---|
| Wegovy penSelf-pay, from Novo Nordisk | $349 | Yes | $199 for each of a new patient’s first two fills at 0.25 or 0.5 mg, through December 31, 2026 |
| Wegovy HD 7.2 mgSelf-pay | $399 | Yes | The highest Wegovy dose |
| Wegovy pillSelf-pay | $149 to $299 | Yes | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg |
| Ozempic penSelf-pay; for type 2 diabetes | $349 to $499 | Yes | $349 at 0.25 to 1 mg, $499 at 2 mg; $199 for a new patient’s first two fills at 0.25 or 0.5 mg, for prescriptions received by December 31, 2026 |
| Medicare | $50 | Yes | Wegovy pen or pill, with prior authorization, through December 31, 2027 |
| Compounded semaglutide17 programs in our index | $119 to $299 | No | All in, month to month; median $199 (checked October 13–18, 2026) |
| NexLifecompounded semaglutide, 12-month plan | $119 | No | $125 on 6 months, $132 on 3 months, $139 month to month; the same at every dose |
Swipe the table sideways to see every column.
Novo Nordisk’s self-pay prices from wegovy.com, the Wegovy savings offer terms and NovoCare’s terms, checked October 27, 2026. A pen month is 28 days, a pill month 30 tablets. Compounded prices from our
With commercial insurance that covers Wegovy, Novo’s savings offer can bring it to as little as $25 a month, with savings up to $100 a month; people in government programs such as Medicare or Medicaid can’t use it. Novo’s self-pay prices are only for an FDA-approved use of each medicine. More ways to pay: semaglutide cost per month.
At NexLife
Compounded semaglutide at NexLife: one price at every dose
It isn’t a generic, and it isn’t FDA-approved. A licensed provider decides if it’s right for you.
| 12-month plan | $119 a month |
|---|---|
| 6-month plan | $125 a month |
| 3-month plan | $132 a month |
| Month to month | $139 a month |
The same at every dose, with no membership fee. Month to month, $139 is $60 under the $199 median of the 17 semaglutide programs in our
Included: a licensed provider who follows your dose, the medication from a state-licensed 503A partner pharmacy, a nutrition plan, a 1:1 coaching call, free expedited shipping and real people 24/7 at
Ways to pay: Affirm, Klarna or Afterpay at checkout, or an HSA or FSA card; NexLife provides a letter of medical necessity for HSA and FSA claims. Already paying less for compounded semaglutide with another licensed provider? Our Price Match Guarantee† matches your regular monthly price. Every plan and price.
The NexLife Price Match Guarantee†
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Fair questions
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email or phone, with 30 days’ notice. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations; your pharmacy’s label will look different. Every plan and price · Price Match Guarantee† terms
Generic semaglutide: your questions
Is there a generic semaglutide in the U.S.?
No: as of October 27, 2026, no generic semaglutide has final FDA approval, and none is sold in the U.S. Apotex says it received the first tentative approval, for a generic Ozempic, on April 10, 2026, but a tentative approval doesn’t allow sales. Novo Nordisk’s brand-name semaglutide is still the only FDA-approved semaglutide.
When will generic Ozempic or Wegovy come to the U.S.?
There’s no public date. Novo Nordisk puts the U.S. expiry of its semaglutide compound patent in 2032; the FDA’s Orange Book lists its drug-substance patent to December 5, 2031. Novo has settled its Ozempic patent cases with seven generic makers, Apotex among them, on terms it says are confidential.
What did the FDA approve for Apotex?
A tentative approval, not a final one. On April 10, 2026, Apotex announced what it calls the first U.S. tentative approval for a generic of Ozempic, its semaglutide injection developed with Orbicular. The FDA says a tentative approval doesn’t allow a company to market the drug; final approval waits until patent or exclusivity issues are resolved.
Is there a generic Wegovy?
Not in the U.S.: none has final FDA approval. In Canada, Apotex announced on June 30, 2026, that Health Canada had approved SEVMIA, its generic of Wegovy for chronic weight management in adults; we found no launch announcement yet. Apotex’s U.S. tentative approval is for a generic of Ozempic.
Can I buy generic semaglutide from Canada?
In most cases, not legally. Generic Ozempic launched in Canada in May 2026, but it isn’t FDA-approved. The FDA says it’s illegal in most circumstances for individuals to import drugs for personal use, and that a drug approved abroad but not in the U.S. is illegal to import. Ask a licensed U.S. provider about legal options.
Is compounded semaglutide a generic?
No. A generic is FDA-approved and must establish therapeutic equivalence to its brand. Compounded semaglutide is made by a state-licensed pharmacy for one person’s prescription and isn’t FDA-approved: the FDA doesn’t verify its safety, effectiveness or quality before it’s sold. A provider prescribes it only when it offers a significant difference for you.
How much is semaglutide without insurance now?
On October 27, 2026, Wegovy pens cost $349 a month self-pay ($399 for Wegovy HD), after $199 for each of a new patient’s first two fills, and the Wegovy pill $149 to $299 by dose. Compounded semaglutide, which isn’t FDA-approved, is $119 a month at NexLife on the 12-month plan, or $139 month to month.
Is “generic semaglutide” sold online real?
Not as an FDA-approved generic: none is approved yet. A site selling “generic semaglutide” to Americans is offering a drug that isn’t approved here, or something that isn’t a generic, such as a “research use only” product the FDA urges consumers not to buy. A site that doesn’t require a prescription is an FDA red flag.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who checked this page
Leads the NexLife clinical team, which medically reviews each of NexLife’s guides, including this one.
The FDA’s approval lists, the companies’ releases, the patents and Novo’s prices checked October 27, 2026.
- How we checked. The U.S. status comes from Apotex’s April 10, 2026 release, the FDA’s Drugs@FDA glossary, its list of 2026 first generic approvals (through August 31, 2026) and Drugs@FDA’s monthly generic approvals for September and October 2026 (through October 26). Patents come from Novo Nordisk’s Form 20-F for 2025 and the FDA’s Orange Book; Canada and India from Health Canada’s and the companies’ own releases; importation and compounding from the FDA; Novo’s prices from wegovy.com, the Wegovy savings offer terms and NovoCare’s terms. We read them all on October 27, 2026. Compounded prices come from our
GLP-1 price index, checked October 13–18, 2026. We don’t predict launch dates or prices. - Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
You know where generics stand. Here’s another route.
Start online in about 3 minutes, and a licensed provider decides if compounded semaglutide is right for you: $119 a month on the 12-month plan, or $139 month to month, at every dose.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, or by secure video where your state requires a live visit. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Apotex: first U.S. FDA tentative approval for a generic version of Ozempic (April 10, 2026). Read October 27, 2026.
- FDA: Drugs@FDA glossary of terms (tentative approval). Read October 27, 2026.
- FDA: First generic drug approvals, 2026. Checked October 27, 2026.
- FDA: Drugs@FDA, original generic (ANDA) approvals, October 2026. Checked October 27, 2026.
- Novo Nordisk: Form 20-F for 2025 (patents and patent litigation). Read October 27, 2026.
- FDA Orange Book: Ozempic (NDA 209637, product 001) patents. Read October 27, 2026.
- FDA Orange Book: Wegovy (NDA 215256, product 001) patents. Read October 27, 2026.
- Health Canada: Canada becomes the first G7 country to approve a generic version of semaglutide (April 28, 2026). Read October 27, 2026.
- Health Canada: Canada approves second generic semaglutide (May 1, 2026). Read October 27, 2026.
- Apotex: Apo-Semaglutide Injection launched in Canada (May 14, 2026). Read October 27, 2026.
- Apotex: Health Canada approval for SEVMIA, a generic semaglutide for chronic weight management (June 30, 2026). Read October 27, 2026.
- Dr. Reddy’s: generic semaglutide injection launched in Canada (May 2026). Read October 27, 2026.
- FDA: Personal importation. Read October 27, 2026.
- FDA: Compounding and the FDA, questions and answers. Read October 27, 2026.
- FDA: Concerns with unapproved
GLP-1 drugs used for weight loss. Read October 27, 2026. - Novo Nordisk: Wegovy cost and coverage. Read October 27, 2026.
- Novo Nordisk: Wegovy savings offer and self-pay terms. Read October 27, 2026.
- NovoCare Pharmacy: terms and self-pay prices for Wegovy and Ozempic. Read October 27, 2026.
- NexLife:
GLP-1 price index. Compounded prices checked October 13–18, 2026. - NexLife: pricing, every plan. Checked October 27, 2026.